Long-Term Bone Loss Studied in Postmenopausal Women
Lower baseline BMI and greater increase in BMI appear to be protective against postmenopausal bone loss
Lower baseline BMI and greater increase in BMI appear to be protective against postmenopausal bone loss
No new safety risks were identified in the studies.
Findings show dose-dependent association with risk higher for multiple injections or higher dose
PF1801 is a novel long-acting glucagon-like peptide-1 receptor agonist.
Initiating oxcarbazepine, but not levetiracetam, linked to increased incidence rate ratio for nontrauma fracture
Titers of anti-S IgG lower for patients with chronic inflammatory disease receiving glucocorticoids or B-cell depletion therapy
Review finds no beneficial effects on muscle function, strength, or mass
Magnitude of elevated risk similar among women who did and did not use bisphosphonates
Six weeks of therapy did not meet the criteria for noninferiority among patients with microbiologically confirmed prosthetic joint infections
Interim results of a randomized study indicate that oral and IV TXA are equally effective in reducing perioperative blood loss